Cipla launches Cipremi, likely to price it Rs 4,000 per vial
It is looking to supply over 80,000 vials within the first month
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Cipla
Pharma firms initiate steps to curb black marketing of remedisivir
Measures include constant monitoring of the drug’s usage and ensuring its uninterrupted supply by working in collaboration with…
Sovereign Pharma releases first batch of remdesivir to Cipla
Cipla is likely to launch Cipremi in two to three days
Experts ask govt to ensure access to remdesivir, raise concerns about supply shortage
Many also allude to an emerging black market for remdesivir in the country through which the drug is being sold at exorbitant…
Mylan gets approval to make and market remdesivir
Jubilant, BDR and Dr Reddy's Labs have also awaiting permission from CDSCO to manufacture and market the drug in India and are…
Cipla and Boehringer Ingelheim to co-market three oral anti-diabetic drugs
The two companies will help co-market three anti-diabetic drugs Oboravo (Empagliflozin), Oboravo Met (Empagliflozin+Metformin) and…
Cipla to price remdesivir version for COVID-19 under 5,000 rupees
Cipla, in an e-mailed statement, did not provide details on when the treatment, called Cipremi, will be available
Cipla launches remdesivir under brand name CIPREMI
The product will be in the form of lyophilised powder for injection 100 mg
Maha govt plans to procure 10000 vials of remdesivir from Cipla
It also plans to procure favipiravir from Glenmark
Cipla, Hetero get DCGI nod to manufacture remdesivir
With this move, domestic production of remdesivir for “restricted emergency use” can begin